Our Investments

Clinical-stage biotech advancing next-generation personalised cancer immunotherapy. FDA RMAT-designated, Phase 3-ready platform leveraging genetic and cellular technologies to enhance the immune response against tumours.

Pioneering robotic surgical technologies enabling complex procedures through smaller access points with greater precision and control. FDA Breakthrough Device designation — redefining minimally invasive surgery.

Advancing L-130, a proprietary non-hallucinogenic psilocin-based therapy for cluster headaches, PTSD, TBI, and rare disease, and S-100 for sickle cell disease. Granted patents extending beyond 2040.

Advancing Emeramide (Irminix®) in Phase 2 clinical trials targeting Progressive Supranuclear Palsy and Parkinson's disease — addressing critical unmet needs in rare neurodegenerative conditions.

Healthcare services platform with $3.25M raised and $65M in claims receivables, optimising specialty care delivery and administrative efficiency across multiple service lines in North America.

Global leader in advanced wound care, co-founded by Dr. Harry Jacobson. Achieved a 12,882x MOIC and 50.7% gross IRR across two IPOs and two LBOs before a landmark $6.2B exit to Apax Partners.

One of the largest US dialysis providers, serving 32,500+ patients across 65 physician-led programmes. Acquired by Fresenius for $4B in 2006 after 40 consecutive quarters of growth and a 28% revenue CAGR.

Pioneer in radiology benefits management, securing a national at-risk contract with Aetna. Evolved into eviCore and acquired by ExpressScripts for $3.6B — returning $324.6M on a $7.5M investment.

Developer and operator of advanced diagnostic imaging centres in partnership with major health systems and Academic Health Centers. Sold to IVC Partners in 2018 at a 7.1x MOIC and 29.2% IRR.